Targeting the epidermal growth factor receptor in colorectal cancer: A potential therapeutic role for gastrin-releasing peptide receptor antagonists [1]

Oncology

Volumn 72, Issue 3-4, 2008, Pages 160-161

  Fernando, Augusta ^a   Brunetto De Farias, Caroline ^a   Roesler, Rafael ^a,b   Schwartsmann, Gilberto ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BOMBESIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GASTRIN RELEASING PEPTIDE RECEPTOR; MONOCLONAL ANTIBODY; RC 3095; RECEPTOR ANTIBODY;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; IN VITRO STUDY; INJECTION SITE REACTION; LETTER; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, BOMBESIN;

EID: 38549167503     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108595     Document Type: Letter

References (10)

1. Italiano A: Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies. Oncology 2006;70:161-167.
2. Cutsem EV: Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 2006;11:1010-1017.
3. Patel O, Shulkes A, Baldwin GS: Gastrin-releasing peptide and cancer. Biochim Biophys Acta 2006;1766:23-41.
4. Schwartsmann G, Di Leone LP, Dal Pizzol F, et al: MAPK pathway activation in colorectal cancer: a therapeutic opportunity for GRP receptor antagonists. Lancet Oncol 2005;6:444-445.
5. Schwartsmann G, Di Leone LP, Horowitz M, et al: A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs 2006;24:403-412.
6. Radulovic S, Miller G, Schally AV: Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Cancer Res 1991;51:6006-6009.
7. Radulovic S, Schally AV, Reile H, et al: Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice. Acta Oncol 1994;33:693-701.
8. Halmos G, Schally AV: Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095. Proc Natl Acad Sci USA 1997;94:956-960.
9. Szepeshazi K, Schally AV, Halmos G, et al: A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers. Proc Natl Acad Sci USA 1997;94:10913-10918.
10. Casanueva FF, Perez FR, Casabiell X, et al: Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines. Proc Natl Acad Sci USA 1996;93:1406-1411.